Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved

Following their successful implementation for the treatment of metastatic breast cancer, the ‘third-generation’ aromatase inhibitors (anastrozole, letrozole, and exemestane) have now become standard adjuvant endocrine treatment for postmenopausal estrogen receptor-positive breast cancers. These drug...

Descripción completa

Detalles Bibliográficos
Autores principales: Lønning, Per Eystein, Eikesdal, Hans Petter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Endocrinology 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689263/
https://www.ncbi.nlm.nih.gov/pubmed/23625614
http://dx.doi.org/10.1530/ERC-13-0099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3689263/
https://www.ncbi.nlm.nih.gov/pubmed/23625614
http://dx.doi.org/10.1530/ERC-13-0099

Ejemplares similares